Back to News
Market Impact: 0.25
Glaukos Expands Retina Pipeline With Novel Biologic Licensing Deal; Stock Down
Source: Nasdaq
Healthcare & BiotechCompany Fundamentals
Glaukos entered an exclusive licensing agreement with RevOpsis to develop and commercialize RO-104, a biologic in development for several retinal diseases, including neovascular age-related macular degeneration and diabetic macular edema. The available article text provides no financial terms, development milestones, or expected timing.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
Ticker Sentiment
GKOS0.65
More News
- Glaukos: The Second J-Code Rewrites The Risk Math
- The world needs Ukraine’s grain. Its farmers are running out of reasons to plant
- Why is the Chinese stock market missing the AI rally
- Tesla drops 'Full Self-Driving' brand name in Europe after regulator pushback
- Why is T-Mobile stock tumbling today?
- SpaceX makes big move into wireless. These once 'obsolete' tech stocks could benefit